Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Spinocerebellar Degenerations 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Colorectal Neoplasms 1

Interventions

pembrolizumab 189Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5durvalumab 5belzutifan 5Nivolumab 5Dexamethasone 5Surgical Procedures, Operative 4Radiotherapy 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × vicriviroc × Clear all
NCT03631407 2024-11-21

MK-7690-046

Merck Sharp & Dohme LLC

Phase 2 Completed
41 enrolled 20 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡